Unmet needs for pulmonary hypertension associated with left heart disease (PH-LHD)
| A better understanding of the natural history |
| Information about the disease prevalence |
| Better definitions of clinical trial study populations and study end-points |
| Availability of specific therapies |
| An understanding of the potential interactions of PH-LHD comorbidities and concomitant medications |
| Improved patient prognosis |